0N6A Stock Overview
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
TME Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.25 |
| 52 Week High | €2.08 |
| 52 Week Low | €0.18 |
| Beta | 1.54 |
| 1 Month Change | -27.58% |
| 3 Month Change | 2.29% |
| 1 Year Change | -84.42% |
| 3 Year Change | -99.41% |
| 5 Year Change | -99.67% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0N6A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.8% | 2.1% | -1.0% |
| 1Y | -84.4% | -22.4% | 2.0% |
Return vs Industry: 0N6A underperformed the German Biotechs industry which returned -21% over the past year.
Return vs Market: 0N6A underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| 0N6A volatility | |
|---|---|
| 0N6A Average Weekly Movement | 21.0% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0N6A's share price has been volatile over the past 3 months.
Volatility Over Time: 0N6A's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 13 | Aram Mangasarian | www.tmepharma.com |
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.
TME Pharma N.V. Fundamentals Summary
| 0N6A fundamental statistics | |
|---|---|
| Market cap | €7.06m |
| Earnings (TTM) | -€6.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs 0N6A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0N6A income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €6.74m |
| Earnings | -€6.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -374.1% |
How did 0N6A perform over the long term?
See historical performance and comparison